← ANALYST RATINGS · TIPRANKS
Royalty Pharma (RPRX): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $66.00, the highest $70.00, the lowest $62.00. The average is +8.3% from the last price of $60.96.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $70.00 | Buy | +14.8% | Reiterated | 12.10.26on TipRanks 07:45 | +1.6%next day −2.1% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $63.00 | Buy | +3.3% | Reiterated | 09.10.26on TipRanks 08:15 | +0.7%next day +1.6% · 5 days +9.0% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $67.00 | Buy | +9.9% | Reiterated | 07.10.26on TipRanks 08:15 | +0.8%next day −0.5% · 5 days +4.9% | ↗ |
| Michael Nedelcovych★★★★★★★★★★#9548 · hits 48% · avg −1.2% | TD Cowen | $65.00 → $68.00+4.6% | Buy | +11.5% | Assigned | 08.09.26on TipRanks 07:30 | −4.7%next day +0.5% · 5 days −2.4% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $66.00 | Buy | +8.3% | Assigned | 08.09.26on TipRanks 06:07 | −4.7%next day +0.5% · 5 days −2.4% | ↗ |
| AI xAi Medical - PharmaceuticalsxAI Grok-3 | TipRanks - xAI | $66.00 → $73.00+10.6% | Buy | +19.8% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI DeepSeek Medical - PharmaceuticalsDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $65.00 → $73.00+12.3% | Buy | +19.8% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI OpenAI Medical - PharmaceuticalsOpenAI 5.2 | TipRanks - OpenAI | $66.00 → $73.00+10.6% | Buy | +19.8% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI Anthropic Medical - PharmaceuticalsAnthropic Opus-4.6 | TipRanks - Anthropic | $62.00 → $69.00+11.3% | Hold | +13.2% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI Google Medical - PharmaceuticalsGemini 3-pro | TipRanks - Google | $66.00 → $73.00+10.6% | Buy | +19.8% | Reiterated | 07.09.26on TipRanks 06:05 | — | |
| AI PerPlexity Medical - PharmaceuticalsPerPlexity SonarPro | TipRanks - PerPlexity | $67.00 → $70.00+4.5% | Buy | +14.8% | Reiterated | 19.08.26on TipRanks 04:06 | — | |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $62.00 | Buy | +1.7% | Reiterated | 10.08.26on TipRanks Aug 11 08:07 | +2.1%next day 0.0% · 5 days +3.0% | ↗ |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $59.00 → $66.00+11.9% | Buy | +8.3% | Reiterated | 06.08.26on TipRanks 07:55 | −0.7%next day −1.5% · 5 days +1.1% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Hold | — | Reiterated | 12.02.26on TipRanks Feb 13 08:15 | +2.8%next day +0.8% · 5 days 0.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Royalty Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 07.10.26: target $66.00 at a price of $56.44 (+16.9%); now: $66.00 at $60.96 (+8.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 10 | 10 | 10 | 8 | 13 | 13 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.18 (from $1.15 to $1.22). Last quarter: $1.32.
Sales
Next quarter’s sales estimate — $885M (from $879M to $892M). Last quarter: $674M.
Best top-analyst consensus in the sector · Healthcare
About Royalty Pharma
- CEO: Pablo Legorreta
- Employees: 100
- 110 East 59th Street, New York, NY, 10022, US
- www.royaltypharma.com
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Data from the stock’s TipRanks forecast page, read 71 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗